List of Excipients in Branded Drug WAINUA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AstraZeneca Pharmaceuticals LP	WAINUA	eplontersen	0310-9400	HYDROCHLORIC ACID	2034-05-01
AstraZeneca Pharmaceuticals LP	WAINUA	eplontersen	0310-9400	SODIUM CHLORIDE	2034-05-01
AstraZeneca Pharmaceuticals LP	WAINUA	eplontersen	0310-9400	SODIUM HYDROXIDE	2034-05-01
AstraZeneca Pharmaceuticals LP	WAINUA	eplontersen	0310-9400	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS	2034-05-01

WAINUA Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

WAINUA (eplontersen) uses a deliberately simple aqueous formulation: sodium chloride for tonicity, tromethamine for buffering, hydrochloric acid for pH adjustment, and water for injection. The commercial value is concentrated less in novel excipients than in sterile manufacturing, prefilled autoinjector performance, cold-chain execution, and intellectual property surrounding the antisense oligonucleotide, GalNAc conjugation, sequence, dosing regimen, and delivery system.

WAINUA was approved by the U.S. Food and Drug Administration in December 2023 for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. AstraZeneca commercializes the product under a collaboration with Ionis Pharmaceuticals. The product is administered subcutaneously at 45 mg once monthly using a single-dose prefilled autoinjector. [1,2]

What excipients are used in WAINUA?

WAINUA contains a short excipient list designed to maintain oligonucleotide stability and support subcutaneous injection.

Component	Function	Commercial and technical relevance
Sodium chloride	Tonicity adjustment	Commodity pharmaceutical ingredient with limited formulation differentiation
Tromethamine	Buffering agent	Controls formulation pH and supports oligonucleotide stability
Hydrochloric acid	pH adjustment	Process-control reagent rather than a differentiated product attribute
Water for injection	Solvent	Requires validated sterile-water and aseptic-processing controls
Eplontersen	Active antisense oligonucleotide	Main source of molecular, analytical, manufacturing, and IP complexity

The FDA label identifies WAINUA as a sterile, clear, colorless-to-yellow solution containing 45 mg of eplontersen in 0.8 mL. The formulation has a pH of approximately 7.5. The label lists tromethamine, sodium chloride, hydrochloric acid, and water for injection as inactive ingredients. [1]

Why does WAINUA use a minimal excipient system?

The formulation avoids surfactants, organic cosolvents, preservatives, and complex lipid systems. That design reduces risks associated with:

• Subcutaneous tolerability
• Aggregation or precipitation
• Extractables and leachables
• Regulatory comparability
• Preservative-related irritation
• Multi-dose container requirements

Eplontersen is a ligand-conjugated antisense oligonucleotide. Its GalNAc conjugate enables hepatocyte uptake through the asialoglycoprotein receptor, allowing lower and less frequent dosing than earlier non-GalNAc antisense products. The formulation therefore does not need to replicate the lipid nanoparticle technology used by patisiran, marketed as ONPATTRO. [1,3]

How does WAINUA’s excipient strategy compare with competing transthyretin drugs?

WAINUA has a simpler injectable formulation than ONPATTRO and a different delivery profile from TEGSEDI and AMVUTTRA.

Product	Active ingredient	Delivery	Key formulation characteristic	Excipient opportunity
WAINUA	Eplontersen	Monthly subcutaneous autoinjector	Simple aqueous solution	Sterile fill-finish, device compatibility, stability
TEGSEDI	Inotersen	Weekly subcutaneous injection	Antisense oligonucleotide formulation	Syringe systems and injection tolerability
AMVUTTRA	Vutrisiran	Quarterly subcutaneous injection	GalNAc-conjugated siRNA formulation	Long-interval dosing and device logistics
ONPATTRO	Patisiran	Intravenous infusion	Lipid nanoparticle formulation	Lipid excipients, infusion handling, cold chain
ATTR-CM small-molecule therapies	Tafamidis	Oral capsule or tablet	Small-molecule solid dosage form	Solid-state, capsule, and oral formulation technologies

WAINUA’s main formulation advantage is operational simplicity. A monthly autoinjector can reduce administration burden relative to weekly injections or intravenous infusion. AMVUTTRA remains a strong competitive benchmark because its quarterly dosing creates a more favorable treatment-frequency profile, although administration is generally performed by a healthcare professional rather than through a patient-operated autoinjector.

What commercial opportunities exist for WAINUA excipients?

The largest opportunities are in qualified supply, sterile processing, and delivery-system integration rather than proprietary excipient substitution.

Pharmaceutical-grade tromethamine

Tromethamine is a relatively standard buffer, but suppliers can compete on:

• Low bioburden and endotoxin control
• Consistent pH and osmolality performance
• Global regulatory documentation
• Supply continuity
• Trace-metal control
• Lot-to-lot impurity profiles

For a commercial antisense product, a second qualified source can reduce supply risk. Qualification is difficult because changes in buffer grade, impurity profile, or manufacturing site may require comparability work and regulatory reporting.

Sodium chloride

Sodium chloride is a low-margin material. Commercial value arises from injectable-grade quality, reliable supply, and validated packaging rather than chemical differentiation. A supplier that can provide regional manufacturing redundancy may have greater commercial leverage than a supplier offering a novel tonicity agent.

Sterile water and aseptic fill-finish

Water for injection is also a commodity input, but the manufacturing platform is strategically important. Opportunities include:

• Low-volume sterile fill-finish
• Prefilled autoinjector assembly
• In-process particulate control
• Container-closure integrity testing
• Cold-chain packaging
• Device labeling and serialization
• Automated visual inspection

A contract development and manufacturing organization with an established platform for 0.8 mL prefilled autoinjectors may capture more value than an excipient manufacturer.

Container-closure and device materials

WAINUA’s commercial presentation places the formulation and device in the same development system. Key technical areas include:

• Silicone oil levels in the syringe
• Stopper and plunger compatibility
• Needle-shield extractables
• Adhesive and polymer contact materials
• Break-loose and glide forces
• Dose delivery accuracy
• Autoinjector activation reliability
• Particulate generation during shipping

Device-compatible materials can become commercially important even when the solution chemistry is conventional. A formulation that performs well in a glass vial may behave differently in a prefilled syringe or autoinjector because of surface interactions, lubrication, and mechanical stress.

What formulation patents protect WAINUA?

The commercial protection for WAINUA is likely broader than its excipient composition. The core defensible areas for eplontersen include:

1. The eplontersen antisense sequence.
2. Specific chemical modifications to the oligonucleotide backbone and sugars.
3. GalNAc conjugation and hepatocyte-targeting architecture.
4. Methods of reducing transthyretin production.
5. Treatment of hereditary transthyretin amyloidosis.
6. Monthly subcutaneous dosing.
7. Formulation stability and injectable presentations.
8. Prefilled syringe or autoinjector configurations.
9. Manufacturing and purification processes.

A simple sodium chloride-tromethamine-water formulation is unlikely to create the strongest standalone barrier unless the claims require a narrow combination of concentrations, pH, stability characteristics, or container system. The higher-value patent claims are more likely to concern the active molecule, conjugate, sequence, treatment method, and manufacturing process.

How strong is WAINUA’s formulation patent position?

The formulation position should be viewed as moderate relative to the molecular and platform position.

Patent category	Likely strategic strength	Relevance to generic entry
Eplontersen composition	High	Directly blocks substitution with the same active oligonucleotide
GalNAc conjugate architecture	High	Can constrain alternative targeted antisense products
Sequence and chemical modifications	High	Creates technical barriers to equivalent-product development
Monthly treatment regimen	Medium to high	May support method-of-use protection
Aqueous excipient formulation	Low to medium	Potentially avoidable through formulation redesign
Autoinjector and presentation	Medium	Can impose device and human-factors burdens
Manufacturing and purification	Medium to high	May restrict access to equivalent-quality active ingredient
Standard excipients individually	Low	Sodium chloride and tromethamine are readily available

The formulation estate becomes more valuable when it is linked to product stability, device compatibility, or manufacturability. A competitor may be able to avoid a narrow excipient claim by changing buffer concentration or pH, but that change could create new stability, tolerability, or regulatory problems.

When does WAINUA lose exclusivity?

FDA approval does not by itself establish a single public patent-expiration date for WAINUA. The relevant exclusivity layers include regulatory exclusivity, Orange Book-listed patents, non-Orange-Book patent rights, and jurisdiction-specific patent-term adjustments.

Protection category	WAINUA position
FDA approval	December 2023
New chemical entity exclusivity	Not the principal framework for a complex oligonucleotide product
Orphan-drug exclusivity	Relevant only if FDA granted the applicable orphan designation and approval protection
Orange Book patents	Must be assessed against the current FDA patent listing for NDA 217388
Composition and conjugate patents	May have terms extending beyond approval and may not all be Orange Book-listed
Method-of-use patents	Potentially relevant to label carve-outs and induced-infringement disputes
Device patents	May affect presentation competition without blocking all active-ingredient competition

Because eplontersen is an oligonucleotide rather than a conventional small molecule, a follow-on applicant may face a more complex pathway than a standard ANDA applicant. The FDA approval route, reference-product designation, patent listing, and equivalence requirements will determine whether a challenger can pursue an ANDA, a 505(b)(2) application, or another pathway.

What is the Orange Book status of WAINUA?

WAINUA is approved under NDA 217388. The Orange Book should be reviewed for current patent listings, expiration dates, and any use codes associated with the product. [4]

Orange Book analysis should distinguish among:

• Patents that claim the drug substance
• Patents that claim the drug product
• Method-of-use patents
• Device or presentation patents
• Patents that are listed but may be vulnerable to a listing challenge
• Patents not eligible for Orange Book listing but still enforceable under ordinary patent law

A patent not listed in the Orange Book can still be asserted against a commercial entrant. Conversely, an Orange Book listing does not guarantee validity or enforceability.

Which companies are challenging WAINUA?

No publicly established Paragraph IV litigation or settlement involving WAINUA is identified in the principal FDA and public-company materials available through June 2024. The absence of a reported challenge is consistent with the product’s recent approval and the technical difficulty of developing a therapeutically equivalent targeted antisense product.

Potential challengers are more likely to include companies with expertise in:

• Oligonucleotide synthesis
• GalNAc conjugation
• Sterile injectable manufacturing
• Complex generics
• RNA medicines
• Specialty pharmacy distribution

Large generic manufacturers could pursue a follow-on product, but the commercial case depends on whether the FDA pathway permits an efficient abbreviated application and whether the reference product’s patent estate can be designed around.

What generic entry risks exist for WAINUA?

The principal risks are unlikely to come from a conventional formulation copy. They are more likely to arise from an alternative complex oligonucleotide product.

Paragraph IV risk

A Paragraph IV filing could challenge listed patents before expiration. The most important possible challenges would address:

• Obviousness of the antisense sequence or conjugate
• Written description and enablement
• Patent-term calculations
• Double-patenting
• Claim scope for monthly dosing
• Orange Book listing eligibility
• Noninfringement through an alternative formulation or device

Biosimilar risk

WAINUA is not a biologic in the conventional FDA biosimilar framework. A biosimilar application under the Public Health Service Act is therefore not the expected route. The more relevant risk is a complex generic, 505(b)(2), or other abbreviated pathway for an oligonucleotide product.

Formulation substitution risk

A competitor could attempt to replace tromethamine with another buffer or modify sodium chloride concentration. That strategy may avoid a narrow formulation claim, but it would require evidence that the alternative formulation maintains:

• Chemical integrity
• Conjugate stability
• Impurity control
• Injection-site tolerability
• Delivered dose accuracy
• Container compatibility
• Shelf life

How do licensing deals affect WAINUA’s commercial opportunity?

WAINUA is the product of Ionis’s antisense platform and AstraZeneca’s development and commercialization capabilities. The partnership reduces commercialization risk for Ionis while giving AstraZeneca access to a targeted RNA therapeutic.

The arrangement creates commercial opportunities across several layers:

Opportunity	Beneficiary
Active pharmaceutical ingredient production	Specialized oligonucleotide manufacturers
GalNAc conjugation and purification	RNA and conjugate CDMOs
Sterile fill-finish	Injectable CDMOs
Autoinjector assembly	Device manufacturers
Cold-chain distribution	Specialty logistics providers
Specialty pharmacy services	Dispensing and patient-support providers
Biomarker and genetic testing	Diagnostic laboratories
Additional indications	Sponsor and licensing partners

The largest upside would come from expansion into transthyretin-mediated cardiomyopathy or other TTR-driven diseases. Such expansion could increase demand but may also trigger new clinical, reimbursement, and patent disputes. AstraZeneca reported WAINUA as a growth product within its rare-disease and cardiovascular portfolio, but public revenue disclosure for the individual product may remain limited during the early launch period. [5]

What manufacturing and IP barriers affect WAINUA?

Eplontersen manufacturing is more difficult than manufacturing a conventional small molecule. Barriers include:

• Solid-phase oligonucleotide synthesis
• Control of truncated sequences and deletion impurities
• Phosphorothioate stereochemical complexity
• GalNAc conjugation
• Chromatographic purification
• Residual solvent and reagent control
• Analytical characterization
• Scale-up yield
• Sterile formulation and fill-finish

The manufacturing process can support patent protection even when the final excipient composition is simple. Process claims may be valuable because an alternative process may produce a different impurity profile or fail to meet clinical-quality specifications.

Geographic coverage also matters. U.S., European, Japanese, and Chinese patent families may have different filing dates, patent-term adjustments, claim scope, and enforcement prospects. A competitor may face a fragmented launch strategy if it can enter one market before another.

What is the best commercial strategy for WAINUA excipients?

The strongest strategy is to treat WAINUA as an integrated drug-device-manufacturing opportunity rather than an excipient-innovation opportunity.

1. Qualify dual sources for tromethamine, sodium chloride, and sterile water.
2. Build a formulation-control strategy around pH, osmolality, particulate matter, and subvisible particles.
3. Develop container-closure data for the prefilled autoinjector.
4. Secure supply of syringe components and device polymers.
5. Validate low-volume sterile fill-finish capacity.
6. Protect manufacturing, packaging, and device interfaces with targeted patents.
7. Avoid unnecessary excipient changes after regulatory approval.
8. Use formulation redesign only where it solves a measurable stability, tolerability, or device problem.

The commercial differentiation is likely to come from reliable delivery of a patient-friendly monthly product, not from replacing standard excipients.

Key Takeaways

• WAINUA uses sodium chloride, tromethamine, hydrochloric acid, and water for injection in a simple aqueous formulation.
• The product is a 45 mg/0.8 mL monthly subcutaneous autoinjector.
• Excipient composition is less defensible than eplontersen’s sequence, GalNAc conjugate, dosing regimen, manufacturing process, and device system.
• The most attractive supplier opportunities are sterile fill-finish, autoinjector integration, container-closure systems, and oligonucleotide manufacturing.
• WAINUA faces complex-generic or 505(b)(2) risk rather than conventional biosimilar risk.
• No established Paragraph IV litigation or settlement is identified in public materials through June 2024.
• Competitive pressure is strongest from AMVUTTRA’s quarterly dosing and from other transthyretin-lowering therapies.
• Excipient changes after approval could create comparability, stability, device, and regulatory burdens.

FAQs

Does WAINUA contain polysorbate or other surfactants?

The FDA label lists tromethamine, sodium chloride, hydrochloric acid, and water for injection. It does not list polysorbate, a preservative, or a lipid nanoparticle excipient. [1]

Can a generic manufacturer copy WAINUA’s excipients?

A follow-on manufacturer may be able to use the same common excipients, but it would still need to establish equivalence, product quality, stability, device performance, and compliance with applicable patent and FDA requirements.

Is WAINUA a biologic eligible for biosimilar competition?

WAINUA is an antisense oligonucleotide drug, not a conventional protein biologic. Biosimilar competition under the standard biologics pathway is not the primary expected route.

Could a different buffer avoid WAINUA formulation patents?

A different buffer could potentially avoid a narrow formulation claim, but it would need to preserve stability, tolerability, pH, osmolality, container compatibility, and delivered-dose performance.

Which WAINUA commercial opportunity has the highest value?

The highest-value opportunities are likely to involve eplontersen or GalNAc-oligonucleotide manufacturing, sterile autoinjector fill-finish, and device-compatible container systems. Individual commodity excipients offer substantially less differentiation.

References

1. U.S. Food and Drug Administration. (2023). WAINUA (eplontersen) injection prescribing information.
2. U.S. Food and Drug Administration. (2023, December 22). FDA approves first treatment for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
3. Ionis Pharmaceuticals, Inc. (2023). Eplontersen clinical and product information.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. AstraZeneca PLC. (2024). Annual report 2023.